SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-23-255009
Filing Date
2023-10-12
Accepted
2023-10-12 16:14:58
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFM14A d554900ddefm14a.htm DEFM14A 446703
2 GRAPHIC g554900dsp008.jpg GRAPHIC 115907
3 GRAPHIC g554900dsp009.jpg GRAPHIC 107412
4 GRAPHIC g554900g48v30.jpg GRAPHIC 48871
  Complete submission text file 0001193125-23-255009.txt   823029
Mailing Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE BUILDING B, SUITE 450 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

IRS No.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-40499 | Film No.: 231322870
SIC: 2834 Pharmaceutical Preparations